HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures

Neuroscience Letters

Volumn 475, Issue 3, 2010, Pages 174-178

  Aksenov, M Y ^a   Aksenova, M V ^a   Mactutus, C F ^a   Booze, R M ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Amyloid peptide; Cell culture; HIV gp120; HIV Tat; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLYCOPROTEIN GP 120; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL VIABILITY; CLADISTICS; CONTROLLED STUDY; FETUS; GLYCOPROTEIN SYNTHESIS; HIPPOCAMPUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; NERVE CELL CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; EMBRYO, MAMMALIAN; HIPPOCAMPUS; HIV ENVELOPE PROTEIN GP120; HIV-1; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TIME FACTORS;

EID: 77952542137     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.03.073     Document Type: Article

References (30)

1. Aksenov M.Y., Aksenova M.V., Carney J.M., Butterfield D.A. Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci. Lett. 1996, 217:117-120.
2. Aksenov M.Y., Aksenova M.V., Nath A., Ray P.D., Mactutus C.F., Booze R.M. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 2006, 27:217-228.
3. Aksenov M.Y., Aksenova M.V., Mactutus C.F., Booze R.M. Attenuated neurotoxicity of the transactivation-defective HIV-1 Tat protein in hippocampal cell cultures. Exp. Neurol. 2009, 219:586-590.
4. Aksenova M.V., Aksenov M.Y., Adams S.M., Mactutus C.F., Booze R.M. Neuronal survival and resistance to HIV-1 Tat toxicity in the primary culture of rat fetal neurons. Exp. Neurol. 2009, 215:253-263.
5. Apcher G.S., Heink S., Zantopf D., Kloetzel P.M., Schmid H.P., Mayer R.J., Krüger E. Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. FEBS Lett. 2003, 553:200-204.
6. Behnisch T., Francesconi W., Sanna P.P. HIV secreted protein Tat prevents long-term potentiation in the hippocampal CA1 region. Brain Res. 2004, 1012:187-189.
7. Brew B.J. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004, 18(Suppl. 1):75-78. Review.
8. Brewer G.J., Lim A., Capps N.G., Torricelli J.R. Age-related calcium changes, oxyradical damage, caspase activation and nuclear condensation in response to glutamate and beta-amyloid. Exp. Gerontol. 2005, 40:426-437.
9. Clifford D.B., Fagan A.M., Holtzman D.M., Morris J.C., Teshome M., Shah A.R., Kauwe J.S. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009, 73:1982-1987.
10. Daily A., Nath A., Hersh L.B. Tat peptides inhibit neprilysin. J. Neurovirol. 2006, 12:153-160.
11. Dong J., Xiong H. Human immunodeficiency virus type 1 gp120 inhibits long-term potentiation via chemokine receptor CXCR4 in rat hippocampal slices. J. Neurosci. Res. 2006, 83:489-496.
12. Giuffrida M.L., Caraci F., Pignataro B., Cataldo S., De Bona P., Bruno V., Molinaro G., Pappalardo G., Messina A., Palmigiano A., Garozzo D., Nicoletti F., Rizzarelli E., Copani A. Beta-amyloid monomers are neuroprotective. J. Neurosci. 2009, 29:10582-10587.
13. Giunta B., Hou H., Zhu Y., Rrapo E., Tian J., Takashi M., Commins D., Singer E., He J., Fernandez F., Tan J. HIV-1 Tat Contributes to Alzheimer's Disease-like Pathology in PSAPP Mice. Int. J. Clin. Exp. Pathol. 2009, 2:433-443.
14. Iwata A., Chen X.H., McIntosh T.K., Browne K.D., Smith D.H. Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes. J. Neuropathol. Exp. Neurol. 2002, 61:1056-1068.
15. Kaul M., Lipton S.A. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J. Neuroimmune Pharmacol. 2006, 1:138-151.
16. Lesné S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., Plotkine M., Marchand-Verracchia C., Vivien D., Buisson A. NMDA receptor activation inhibits α-secretase and promotes neuronal amyloid-β production. J. Neurosci. 2005, 12:9367-9377.
17. Mishra M., Vetrivel S., Siddappa N.B., Ranga U., Seth P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann. Neurol. 2008, 63:366-376.
18. Puzzo D., Privitera L., Leznik E., Fà M., Staniszewski A., Palmeri A., Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 2008, 28:14537-14545.
19. Pulliam L. HIV regulation of amyloid beta production. J. Neuroimmune Pharmacol. 2009, 4:213-217.
20. Ranga U., Shankarappa R., Siddappa N.B., Ramakrishna L., Nagendran R., Mahalingam M., Mahadevan A., Jayasuryan N., Satishchandra P., Shankar S.K., Prasad V.R. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J. Virol. 2004, 78:2586-2590.
21. Rempel H.C., Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005, 19:127-135.
22. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defense via pattern recognition receptors. Prog. Neurobiol. 2009, 87:181-194. Review.
23. Seeger M., Ferrell K., Frank R., Dubiel W. HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J. Biol. Chem. 1997, 272:8145-8148.
24. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113. Review.
25. Uversky V.N., Kabanov A.V., Lyubchenko Y.L. Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi. J. Proteome Res. 2006, 5:2505-2522. Review.
26. Valcour V., Shikuma C., Shiramizu B., Watters M., Poff P., Selnes O., Holck P., Grove J., Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004, 63:822-827.
27. Wakabayashi M., Matsuzaki K. Formation of amyloids by Abeta-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. J. Mol. Biol. 2007, 371:924-933.
28. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
29. Xiong H., Zeng Y.C., Zheng J., Thylin M., Gendelman H.E. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. J. Neurovirol. 1999, 5:519-528.
30. Xu J., Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J. Neuroimmune Pharmacol. 2009, 4:200-212. Review.